Drug intelligence / Profile preview

Kapilar

Development stage: Unknown
Lead developer: Diod
Modality: Small Molecules
Administration: Oral

Overview

Kapilar is a dietary supplement developed by the Russian company Diod, primarily marketed for supporting venous circulation and cardiovascular health. Its main active ingredient is dihydroquercetin (also known as taxifolin), a bioflavonoid extracted from Siberian larch (Larix sibirica). Dihydroquercetin is recognized for its potent antioxidant properties and its ability to protect capillary walls, reduce capillary permeability, and improve microcirculation. It is used as a complementary approach for conditions such as chronic venous insufficiency and to support overall vascular integrity. The product is officially registered in Russia as a biologically active supplement (БАД) and is not classified as a medicinal drug.

Brand names: КАПИЛАРKapilar
Other names: Kapilar-Diod

Targets

HYAL (Hyaluronidase family (HYAL))

Beyond the preview

Go deeper on Kapilar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kapilar.

Explore the full profile